Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

By J. Piek, P. V. van Diest, R. Zweemer, J. Jansen, R. Poort‐Keesom, F. Menko, J. Gille, A. Jongsma, G. Pals, P. Kenemans and 1 more. Journal of Pathology, 2001

782 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/b32c97073622c12a62da0e01c171141c564f854c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Prat
2. Ie-Ming Shih
3. E. Lengyel
4. C. Lord
5. R. Kurman

In Pathology and Forensic Medicine

1. F. Balkwill

In Reproductive Medicine

1. J. Prat
2. R. Kurman
3. Ie-Ming Shih
4. E. Lengyel
5. A. Oza
6. C. Lord

Citations in the corpus

• Rethinking Ovarian Cancer: Recommendations for Improving Outcomes (2011, positive): “For example, the distal fallopian tube has been identified as a source of high-grade serous ovarian cancer”
• Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, positive): “Therefore, there was surprise and skepticism when a group of Dutch investigators in 2001 first described tubal intraepithelial carcinomas (TICs), later designated “serous tubal intraepithelial carcinomas (STICs)” and occult invasive HGSCs in the fallopian tube that closely resembled ovarian HGSC, in”
• A candidate precursor to serous carcinoma that originates in the distal fallopian tube (2007, background): “However, a precursor to high-grade serous ovarian cancer has not been demonstrated and universally accepted [8–13].”
• The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome (2006, background): “Some have used immunostaining for Ki-67 or p53, reporting increased localization in the epithelia of cases relative to controls.(10) Another report linked prior inflammation to tubal carcinoma.”
• The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory (2010, result): “Sporadic reports of tubal carcinoma and ‘‘dysplasia’’ had been reported in the past,(15) but in 2001, a group of Dutch investigators described these lesions that closely resemble high-grade ovarian serous carcinoma in women with a genetic predisposition to ovarian cancer.(33) This was a surprising f”
• Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention (2017, background): “Recent studies suggest that ovarian cancer may actually originate from the fallopian tube (23, 24), rather than from ovarian surface epithelial cells; therefore, the next group of experiments tested whether loss of BRCA1 in immortalized fallopian tube cells increased aerobic glycolysis.”
• Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (2012, background): “The traditional view that HGSC arise exclusively from ovarian surface epithelium or epithelial inclusion cysts has been recently challenged by the identification, in women with BRCA1 or BRCA2 germline mutations, of TIC in the distal fimbriated end of the fallopian tube as the probable precursor of a”
• Staging classification for cancer of the ovary, fallopian tube, and peritoneum (2014, background): “Another discovery that influenced the new FIGO staging occurred in 2001, when patients with BRCA mutation (breast–ovarian cancer syndrome) undergoing risk-reducing salpingo-oophorectomy were found to have high-grade serous tubal intraepithelial carcinoma (STIC) not in the ovary but in the fallopian ”